Itonis Pharmaceuticals and Dr. Charles Hensley Placed First Purchase Order to Produce Emesyl Nausea Remedy
September 23 2013 - 08:00AM
OTC Markets
Itonis Pharmaceuticals and Dr. Charles Hensley Placed First
Purchase Order to Produce Emesyl Nausea Remedy
Itonis Pharmaceuticals and Dr. Charles Hensley Placed First
Purchase Order to Produce Emesyl Nausea Remedy
LAGUNA HILLS, CA--(Marketwired - Sep 23, 2013) - Itonis, Inc.
(PINKSHEETS: ITNS) and Charles Hensley, PhD., the inventor of the
Zicam? cold remedy, are pleased to announce that the first order
for Emesyl?, the company's over-the-counter homeopathic product for
the relief of nausea, has been placed with Oasis Health Product,
Inc.
Dr. Hensley commented, "I am pleased with the progress the
company has made in getting this product ready for market."
About Itonis
Pharmaceuticals
Itonis Pharmaceuticals, a new division of
Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's
mission is to create and market over-the-counter and prescription
homeopathic products that better people's lives. Dr. Hensley is a
pioneer in the development and marketing of safe and effective
therapeutic nutraceutical and homeopathic preparations. He was a
founder of the company that launched the Zicam? Cold Remedy, making
the product a household name and forever changing the marketing and
product placement paradigm for homeopathic drugs in the United
States. Dr. Hensley and his team plan to use the same methodologies
to revolutionize the treatment of several other common ailments and
other chronic diseases.
About Itonis,
Inc.
Itonis, Inc. (the "Company") was incorporated in the state of
Nevada on July 5, 2005 under the name of Kenshou, Inc., which later
changed to Itonis, Inc. on December 2, 2005. For more information,
please visit www.itonisholdings.com.
Safe
Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Mar 2023 to Mar 2024